Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Optic nerve disease and axon pathophysiology.
Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple SclerosisImpact of Fingolimod Therapy in Multiple Sclerosis.
Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis.
Sleep Disorders and Multiple Sclerosis: A Clinical and Polysomnography Study.
Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients.
Regional Cervical Cord Atrophy and Disability in Multiple Sclerosis: A Voxel-based Analysis.
Vitamin A and systemic inflammation as protective factors in multiple sclerosis.
Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program.
The role of growth factors as a therapeutic approach to demyelinating disease.
An Inventory of Short Term and Long Term Changes in Gene Expression Under Interferon β Treatment of Relapsing Remitting MS Patients.
Separated at birth? The functional and molecular divergence of OLIG1 and OLIG2.
Simvastatin shows promise in treating progressive multiple sclerosis, study finds.
Exploring brainstem function in multiple sclerosis by combining brainstem reflexes, evoked potentials, clinical and MRI investigations.
Human neural precursor cells promote neurologic recovery in a viral model of multiple sclerosis.
Expression of IL-33 and its epigenetic regulation in Multiple Sclerosis.
Teva to initiate third Phase III trial of oral laquinimod for the treatment of relapsing remitting multiple sclerosis
Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates.
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).
The site of production of superoxide radical in mitochondrial Complex I is not a bound ubisemiquinone but presumably iron-sulfur cluster N2.
Genzyme receives Complete Response Letter from FDA on Lemtrada™ (alemtuzumab) application
CD4 cell response to interval therapy with natalizumab.
Celgene to Acquire Receptos, Advancing Leadership in Immune-Inflammatory Diseases
Optic neuritis in a child with biotinidase deficiency: case report and literature review.
Influence of pregnancy on neuromyelitis optica spectrum disorder.
Activities of daily living: evaluation and treatment in persons with multiple sclerosis.

Pages